Lymphangiogenic growth factors, receptors and therapies

被引:90
作者
Lohela, M
Saaristo, A
Veikkola, T
Alitalo, K [1 ]
机构
[1] Univ Helsinki, Cent Hosp, Mol Canc Biol Lab, Biomedicum, Helsinki 00014, Finland
[2] Univ Helsinki, Cent Hosp, Ludwig Inst Canc Res, Biomedicum,Haartman Inst, Helsinki 00014, Finland
关键词
LEC; VEGF; AAV;
D O I
10.1160/TH03-04-0200
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The lymphatic vasculature is essential for the maintenance of normal fluid balance and for the immune responses, but it is also involved in a variety of diseases. Hypoplasia or dysfuction of the lymphatic vessels can lead to lymphedema, whereas hyperplasia or abnormal growth of these vessels are associated with lymphangiomas and lymphangiosarcomas. Lymphatic vessels are also involved in,lymph node and systemic metastasis of cancer cells. Recent novel findings on the molecular mechanisms involved in lymphatic vessel development and regulation allow the modulation of the lymphangiogenic process and specific targeting of the lymphatic endothelium. Recent results show that the homeodomain transcription factor Prox-I is an important lymphatic endothelial cell (LEC) fate-determining factor. which can induce LEC-specific gene transcription even in blood vascular endothelial cells (BECs). This suggests that the distinct phenotypes of cells in the adult vascular endothelium are plastic and sensitive to transcriptional reprogramming, which might be useful for future therapeutic applications involving endothelial cells Vascular endothelial growth factor-C (VEGF-C) and VEGF-D are peptide growth factors capable of inducing the growth of new lymphatic vessels in vivo in a process called lymphangiogenesis. They belong to the larger family which also includes VEGF, placenta growth factor (PIGF) and VEGF-B.VEGF-C and VEGF-D are ligands for the endothelial cell specific tyrosine kinase receptors VEGFR-2 and VEGFR-3. In adult human as well as mouse tissues VEGFR-3 is expressed predominantly in lymphatic endothelial cells which line the inner surface of lymphatic vessels. While VEGFR-2 is thought, to be the main mediator of angiogenesis,VEGFR-3 signaling is crucial for the development of the lymphatic vessels. Heterozygous inactivation of the VEGFR-3 tyrosine kinase leads to primary lymphedema due to defective lymphatic drainage in the limbs. Other factors that seem to be involved in lymphangiogenesis include the Tie/angiopoietin system, neuropilin-2 and integrin alpha9. VEGF-C induces lymphatic vessel growth, but high levels of VEGF-C also resulted in blood vessel leakiness and growth. The VEGFR-3-specific mutant form of VEGF-C called VEGF-C 156S lacks blood vascular side effects but is sufficient for therapeutic lymphangiogenesis in a mouse model of lymphedema. As VEGF-C 156S is a specific lymphatic endothelial growth factor in the skin, it provides an attractive molecule for pro-lymphangiogenic therapy.
引用
收藏
页码:167 / 184
页数:18
相关论文
共 228 条
[1]  
Achen MG, 2001, J PATHOL, V193, P147, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH757>3.0.CO
[2]  
2-G
[3]   Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) [J].
Achen, MG ;
Jeltsch, M ;
Kukk, E ;
Mäkinen, T ;
Vitali, A ;
Wilks, AF ;
Alitalo, K ;
Stacker, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :548-553
[4]   Heterogeneity of angiogenic activity in a human liposarcoma: A proposed mechanism for "no take" of human tumors in mice [J].
Achilles, EG ;
Fernandez, A ;
Allred, EN ;
Kisker, O ;
Udagawa, T ;
Beecken, WD ;
Flynn, E ;
Folkman, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14) :1075-1081
[5]   Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues [J].
Akagi, K ;
Ikeda, Y ;
Miyazaki, M ;
Abe, T ;
Kinoshita, J ;
Maehara, Y ;
Sugimachi, K .
BRITISH JOURNAL OF CANCER, 2000, 83 (07) :887-891
[6]   VASCULAR ENDOTHELIAL GROWTH-FACTOR ACTS AS A SURVIVAL FACTOR FOR NEWLY FORMED RETINAL-VESSELS AND HAS IMPLICATIONS FOR RETINOPATHY OF PREMATURITY [J].
ALON, T ;
HEMO, I ;
ITIN, A ;
PEER, J ;
STONE, J ;
KESHET, E .
NATURE MEDICINE, 1995, 1 (10) :1024-1028
[7]  
[Anonymous], CANCER
[8]  
APRELIKOVA O, 1992, CANCER RES, V52, P746
[9]   Posttranslational modifications of recombinant myotube-synthesized human factor IX [J].
Arruda, VR ;
Hagstrom, JN ;
Deitch, J ;
Heiman-Patterson, T ;
Camire, RM ;
Chu, K ;
Fields, PA ;
Herzog, RW ;
Couto, LB ;
Larson, PJ ;
High, KA .
BLOOD, 2001, 97 (01) :130-138
[10]   Isolation of putative progenitor endothelial cells for angiogenesis [J].
Asahara, T ;
Murohara, T ;
Sullivan, A ;
Silver, M ;
vanderZee, R ;
Li, T ;
Witzenbichler, B ;
Schatteman, G ;
Isner, JM .
SCIENCE, 1997, 275 (5302) :964-967